Exocrine Pancreatic Insufficiency Therapeutics Market Research Report By Drug Class (Pancreatic Enzyme Replacement Therapy (PERT), Proton Pump Inhibitors (PPIs), Histamine-2 Receptor Antagonists (H2RAs), Anticholinergics), By Route of Administration (Oral, Intravenous, Subcutaneous), By Indication (Chronic Pancreatitis, Pancreatic Cancer, Cystic Fibrosis, Short Bowel Syndrome), By Patient Population (Adults, Children, Elderly) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Global Exocrine Pancreatic Insufficiency Therapeutics Market Overview:

As per MRFR analysis, the Exocrine Pancreatic Insufficiency Therapeutics Market Size was estimated at 1.53 (USD Billion) in 2022. The Exocrine Pancreatic Insufficiency Therapeutics Market Industry is expected to grow from 1.61 (USD Billion) in 2023 to 2.6 (USD Billion) by 2032. The Exocrine Pancreatic Insufficiency Therapeutics Market CAGR (growth rate) is expected to be around 5.48% during the forecast period (2024 - 2032).

Key Exocrine Pancreatic Insufficiency Therapeutics Market Trends Highlighted

The Exocrine Pancreatic Insufficiency Therapeutics Market displays promising growth prospects driven by the rising prevalence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer. Other factors contributing to market growth include advancements in enzyme replacement therapy, increased awareness about disease management, and favorable reimbursement policies. The market is expected to witness a surge in demand for novel therapeutic options due to the unmet medical needs of patients. Key trends include the development of targeted therapies, combination therapies, and personalized treatment approaches. Opportunities exist in exploring the use of artificial intelligence for diagnosis and treatment optimization. The market is also poised for growth with the increasing adoption of telehealth services and remote patient monitoring solutions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Therapeutics Market Drivers

Rising Prevalence of Chronic Pancreatitis

Chronic pancreatitis is a major cause of exocrine pancreatic insufficiency (EPI), a condition in which the pancreas does not produce enough digestive enzymes. The rising prevalence of chronic pancreatitis is a key driver of the growth of the Exocrine Pancreatic Insufficiency Therapeutics Market Industry. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 800,000 people in the United States have chronic pancreatitis.The increasing incidence of chronic pancreatitis is attributed to factors such as the rising prevalence of obesity, alcohol abuse, and smoking. Obesity is a major risk factor for chronic pancreatitis, as it can lead to the formation of gallstones, which can block the pancreatic duct and cause inflammation. Alcohol abuse can also damage the pancreas and lead to chronic pancreatitis. Smoking is another risk factor for chronic pancreatitis, as it can damage the blood vessels that supply the pancreas.The rising prevalence of chronic pancreatitis is expected to continue to drive the growth of the Exocrine Pancreatic Insufficiency Therapeutics Market Industry in the coming years.

Increasing Awareness of EPI

Exocrine pancreatic insufficiency is a pathological state in which the pancreas cannot produce digestive enzymes enough. This condition can cause a wide variety of symptoms, such as acute abdominal pain, diarrhea, body weight loss, and malnutrition. Until recently, this disease was underdiagnosed or wrongly classified. However, due to the escalation of public awareness of the condition, more and more people are being correctly diagnosed, and their treatment, both conservative and surgical, is enhanced.The permanent rise in awareness is a driving factor in the growth of the Exocrine Pancreatic Insufficiency Therapeutics Market Industry. There are several factors that contribute to the raised awareness of the disease: Public health campaigns, Educational programs aimed at healthcare specialists, Emergence of new diagnostic tests, which facilitate the identification of the disease, Intensification of the development of effective treatments, pharmaceutical or surgical Due to these factors, the awareness of the EPI continues to grow.Consequently, more cases of this disease are diagnosed and treated. Hence, it is possible to expect a continued raise in demand for Exocrine Pancreatic Insufficiency Therapeutics in the nescient years.

Technological Advancements in EPI Treatment

Technological advancements are also driving the growth of the Exocrine Pancreatic Insufficiency Therapeutics Market Industry. These advancements include the development of new and more effective treatments for EPI. For example, new enzyme replacement therapies (ERTs) are being developed that are more effective and easier to use. In addition, new drugs are being developed that can help to reduce the symptoms of EPI. These technological advancements are expected to lead to improved outcomes for patients with EPI and a continued increase in demand for Exocrine Pancreatic Insufficiency Therapeutics.

Exocrine Pancreatic Insufficiency Therapeutics Market Segment Insights:

Exocrine Pancreatic Insufficiency Therapeutics Market Drug Class Insights

The Exocrine Pancreatic Insufficiency Therapeutics Market is segmented based on drug class into Pancreatic Enzyme Replacement Therapy (PERT), Proton Pump Inhibitors (PPIs), Histamine-2 Receptor Antagonists (H2RAs), and Anticholinergics. Among these, PERT held the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of the PERT segment can be attributed to the increasing prevalence of chronic pancreatitis, which is the leading cause of exocrine pancreatic insufficiency. PPIs are another important drug class used in the treatment of exocrine pancreatic insufficiency.PPIs work by reducing the production of stomach acid, which can help to improve the absorption of pancreatic enzymes. The H2RAs segment is also expected to witness significant growth over the forecast period, owing to their effectiveness in reducing stomach acid secretion. Anticholinergics are another class of drugs used to treat exocrine pancreatic insufficiency. The growth of the market can be attributed to the increasing prevalence of chronic pancreatitis, the rising geriatric population, and the growing awareness of exocrine pancreatic insufficiency.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Therapeutics Market Route of Administration Insights

Segmentation of the Exocrine Pancreatic Insufficiency Therapeutics Market The Exocrine Pancreatic Insufficiency Therapeutics Market is segmented into oral, intravenous, and subcutaneous routes. The oral route of administration is projected to be the leading route of administration with the highest revenue share which is probably due to the convenience, ease of administration, and lower costs of oral administration. A report on the Exocrine Pancreatic Insufficiency Therapeutics Market data suggests that the oral route of administration will hence grow at a moderate rate to have a market size of around 1.2 billion USD by 2024.The intravenous route of administration appears to hold a significant share, possibly because in severe conditions of exocrine pancreatic insufficiency, patients require controlled and immediate delivery of the drug. This route of administration will also be popular in hospitals and other healthcare facilities that have not been approved to administer drugs. The Exocrine Pancreatic Insufficiency Therapeutics Market segmentation data suggests that the intravenous route of administration will grow at a medium rate to reach a market size of around 0.6 billion USD by 2024.Finally, the subcutaneous route of administration will appear to have the least share of the market due to the lesser need for subcutaneous administration. This route of administration will involve the hypodermic or subdermal administration of the drug. This route is used when an alternative route of administration is unsuitable. The Exocrine Pancreatic Insufficiency Therapeutics Market statistics suggest that the subcutaneous route of administration will also grow at a slow rate to have a market size of around 0.2 billion USD by 2024.

Exocrine Pancreatic Insufficiency Therapeutics Market Indication Insights

The Exocrine Pancreatic Insufficiency Therapeutics Market is segmented by indication into chronic pancreatitis, pancreatic cancer, cystic fibrosis, and short bowel syndrome. Among these, chronic pancreatitis held the largest revenue share in 2023 and is expected to maintain its dominance throughout the forecast period. The high prevalence of chronic pancreatitis, coupled with the increasing demand for effective treatment options, is driving the growth of this segment. Pancreatic cancer is another major indication, with a significant unmet medical need.The rising incidence of pancreatic cancer and the lack of effective treatment options are fueling the demand for novel therapeutics in this segment. Cystic fibrosis and short bowel syndrome are also significant indications, with growing patient populations and a need for specialized treatment approaches. The Exocrine Pancreatic Insufficiency Therapeutics Market is expected to witness steady growth in the coming years, driven by the increasing prevalence of chronic pancreatitis and pancreatic cancer, as well as the development of new and more effective treatment options.

Exocrine Pancreatic Insufficiency Therapeutics Market Patient Population Insights

The Exocrine Pancreatic Insufficiency Therapeutics Market segmentation based on Patient Population includes Adults, Children, and Elderly. Among these segments, Adults are expected to hold the largest market share due to the higher prevalence of chronic pancreatitis and other conditions leading to exocrine pancreatic insufficiency in this population. The increasing geriatric population is also anticipated to contribute to the growth of the Elderly segment in the coming years. The Children segment is projected to witness a steady growth rate owing to the rising incidence of cystic fibrosis and other genetic disorders that can cause exocrine pancreatic insufficiency in children.

Exocrine Pancreatic Insufficiency Therapeutics Market Regional Insights

The Exocrine Pancreatic Insufficiency Therapeutics Market is segmented into North America, Europe, APAC, South America, and MEA. North America is expected to hold the largest market share in 2024, followed by Europe. APAC is expected to be the fastest-growing region during the forecast period 2024-2032. The growth in the North American market can be attributed to the increasing prevalence of exocrine pancreatic insufficiency, the rising demand for effective therapies, and the presence of key market players in the region. The European market is also expected to grow steadily due to the increasing awareness of exocrine pancreatic insufficiency and the availability of advanced treatment options.The APAC market is expected to witness significant growth over the forecast period due to the rising incidence of exocrine pancreatic insufficiency, the increasing demand for affordable therapies, and the growing healthcare infrastructure in the region. The South American and MEA markets are also expected to grow at a steady pace due to the increasing awareness of exocrine pancreatic insufficiency and the growing demand for effective therapies.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Therapeutics Market Key Players And Competitive Insights:

The leading Exocrine Pancreatic Insufficiency Therapeutics Market players are interested in developing new products that would perfectly meet the needs of the target patients, investing in the research and development area to increase the efficiency and safety of the new products. In general, the industry might be expected to grow considerably during the next several years as the prevalence rate of different pancreatic diseases continues to increase, and the need for safe and efficient treatment options that can positively affect people with chronic diseases remains relevant. Currently, the leading Exocrine Pancreatic Insufficiency Therapeutics Market players use various strategies to attract more attention from customers and get a competitive edge, including mergers, acquisitions, collaborations, and partnerships. The major driving factor for the Exocrine Pancreatic Insufficiency Therapeutics Market is the high demand for new, effective, and safe procedures to improve the state of many patients suffering from exocrine pancreatic insufficiency.The current leaders of the Exocrine Pancreatic Insufficiency Therapeutics Market include Johnson Johnson. The company offers such products as Creon and Pancrease for exocrine pancreatic insufficiency. Johnson Johnson is also one of the companies that invest in new product development to present new solutions to patients with exocrine pancreatic insufficiency.Another major player in the Exocrine Pancreatic Insufficiency Therapeutics Market is Abbott Laboratories. The company delivers such products as pancrelipase and Zenpep to deal with exocrine pancreatic insufficiency. At present, Abbott Laboratories also contributes much effort and money to research and development, and the successful fusion of the development with the availability of a wide product range should help the company preserve its leading position.

Key Companies in the Exocrine Pancreatic Insufficiency Therapeutics Market Include:

• Pepsico, Inc.


• Baxter Healthcare Corporation


• Shire Pharmaceuticals


• Viokace B.V.


• Amgen


• Creon Pharma GmbH


• Amway


• Novo Nordisk


• Fresenius Kabi AG


• Pancrex Pharmaceuticals Inc


• AstraZeneca plc


• Merck Co., Inc.


• AbbVie


• Eli Lilly and Company


• Johnson Johnson

Exocrine Pancreatic Insufficiency Therapeutics Market Industry Developments

The Exocrine Pancreatic Insufficiency Therapeutics Market is anticipated to reach a value of USD 2.6 billion by 2032, expanding at a CAGR of 5.48% from 2024 to 2032. The rising prevalence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer is driving the market growth. Furthermore, increasing awareness of enzyme replacement therapy and the availability of advanced treatment options are contributing to market expansion. Key players in the market include AbbVie, Eli Lilly, and Novo Nordisk. Recent developments include the launch of new products such as Creon and Pancreaze, as well as the development of novel therapies such as gene therapy and stem cell therapy.

Exocrine Pancreatic Insufficiency Therapeutics Market Segmentation Insights

Exocrine Pancreatic Insufficiency Therapeutics Market Drug Class Outlook

• Pancreatic Enzyme Replacement Therapy (PERT)


• Proton Pump Inhibitors (PPIs)


• Histamine-2 Receptor Antagonists (H2RAs)


• Anticholinergics

Exocrine Pancreatic Insufficiency Therapeutics Market Route of Administration Outlook

• Oral


• Intravenous


• Subcutaneous

Exocrine Pancreatic Insufficiency Therapeutics Market Indication Outlook

• Chronic Pancreatitis


• Pancreatic Cancer


• Cystic Fibrosis


• Short Bowel Syndrome

Exocrine Pancreatic Insufficiency Therapeutics Market Patient Population Outlook

• Adults


• Children


• Elderly

Exocrine Pancreatic Insufficiency Therapeutics Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa